Piper Sandler Maintains Neutral on Travere Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Nicole Gabreski has maintained a Neutral rating on Travere Therapeutics (NASDAQ:TVTX) and lowered the price target from $19 to $10.
October 25, 2023 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Travere Therapeutics and lowered the price target from $19 to $10.
The lowering of the price target by Piper Sandler from $19 to $10 indicates a negative outlook for Travere Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100